Treatment Option for Advanced Ovarian Cancer | ZEJULA (niraparib)
WEBZEJULA tablet is a prescription medicine used for the: maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.
Ovarian Cancer Treatment | ZEJULA (niraparib) for HCPs
WEBZEJULA (niraparib) tablets 100 mg/200 mg/300 mg are indicated: for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to …
ZEJULA Resources for Healthcare Professionals | ZEJULA (niraparib)
WEBFind ZEJULA resources for healthcare professionals. Download clinical tools, view product information, and find materials to share with your patients.
Zejula: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBSep 25, 2023 · Zejula (niraparib) is used to treat recurrent ovarian, fallopian tube, or peritoneal cancer. Includes Zejula side effects, interactions and indications.
FDA approves Zejula (niraparib) as the only once-daily PARP ... - GSK
WEBApr 29, 2020 · Zejula is the only once-daily PARP inhibitor approved in the US as monotherapy for women with advanced ovarian cancer beyond those with BRCAm disease in the first-line and recurrent maintenance treatment settings, as well as late-line primary treatment settings.
Risks & Side Effects | ZEJULA (niraparib)
WEBZEJULA tablet is a prescription medicine used for the: maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.
Financial, Cost & Co-pay Assistance | ZEJULA (niraparib)
WEBZEJULA tablet is a prescription medicine used for the: maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.
DailyMed - ZEJULA- niraparib tablet, film coated
WEBMay 2, 2024 · ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. •
FDA approves niraparib for first-line maintenance of advanced …
WEBOn April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube,...
ZEJULA | GSK Canada
WEB16 February 2023 – Important Safety Information on ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting (PDF - 129 KB)
- Some results have been removed